http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106957312-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 |
| filingDate | 2016-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106957312-B |
| titleOfInvention | Raltitrexed hydrate crystal form and preparation method thereof |
| abstract | The invention belongs to the field of drug synthesis, and in particular relates to a crystal form of raltitrexed and a preparation method thereof. The crystal form of raltitrexed in the present invention is a hydrate, and the molar ratio of raltitrexed to water is 1:0.5-3. In the present invention, a new crystal form of raltitrexed is prepared by dissolving raltitrexed in a mixed solvent of water and an organic solvent, and then adding anti-solvent water dropwise thereto, wherein the organic solvent is tetrahydrofuran, 1,4-di Oxyhexane. The crystal form of the invention can maintain good storage stability, is easy for industrial production, has no hygroscopicity, avoids water absorption, provides convenience for transportation, production, and pharmaceutical preparations, and has certain medicinal prospects. |
| priorityDate | 2016-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.